Background. The impact of multidrug-resistant organisms (MDROs), including non-fermentative bacilli (NFBs), is rising and underestimated, especially in intensive care units (ICUs). The growing prevalence of multidrug resistance (MDR) and extensive drug resistance (XDR) is challenging for clinicians, as the treatment options are limited.
Introduction
The impact of multidrug-resistant organisms (MDROs), including non-fermentative bacilli (NFBs), in intensive care units (ICUs) is rising and underestimated. 1 Pseudomonas aeruginosa (PAR) shows an intrinsic resistance to many antibiotics and can horizontally acquire novel resistance genes. 2 This may be one of the reasons for the increasing number of reports of multi-drug resistant (MDR) strains. 3 In particular, nosocomial isolates of Acinetobacter and Pseudomonas may exhibit high rates of resistance to antimicrobials. Carbapenems are important agents for the treatment of severe infections caused by P. aeruginosa and A. baumannii. Carbapenem resistance poses a real threat to prognosis, because treatment options are limited. Carbapenems are one of the groups of antibiotics with enhanced activity, but these agents can also be inactivated by various mechanisms. 4 Colistin is a key therapeutic option for the treatment of carbapenem-resistant A. baumannii and P. aeruginosa, alone or in combination with other agents, such as tigecycline, ampicillin-sulbactam, and carbapenems. Monotherapy is usually recommended for uncomplicated infections, while combination therapy is normally recommended for severe infections, such as bacteremia and pneumonia, although at least in some cases, the advantage of combination therapy remains a matter of debate. 5 It is supposed that colistin resistance emerges under selective pressure in individual patients rather than through patient-to-patient transmission. 6 A surveillance study of US hospitals revealed that 5.3% of all Acinetobacter strains were resistant to colistin. 7 In recent decades, a substantial reduction in mortality rates in ICUs has been reported, but the antimicrobial resistance profile of microorganisms causing infections has significantly changed. Several factors may explain the rapid spread of MDROs in ICUs: new mutations, the selection of resistant strains, and poor antibiotic management. Most guidelines have different recommendations depending on the risk of the presence of MDROs.
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Objectives
Modern medicine requires clear and explicit criteria to describe the phenomena of public health, and one of the major problems of public health is microbial drug resistance. The aim of this study was to analyze the extent of the epidemiological problem of highly multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) non-fermentative bacilli isolated from pneumonia and bloodstream infections (BSIs) in patients hospitalized in southern Poland.
Material and methods
Population description
This laboratory-based, multicenter study comprised consecutive non-repetitive NFB isolates received from pneumonia and BSIs, from hospitalized and non-hospitalized patients throughout southern Poland (Małopolska and Silesia regions), collected between January 1, 2013 and December 31, 2013. The study included patients from 12 hospitals, 3 long-term care and outpatient care facilities operated by the Chair of Microbiology at Jagiellonian University Medical College (Kraków, Poland), and 2 collaborative laboratories from the Silesia region. Pneumonia and BSI were diagnosed in accordance with the definitions of the European Center for Disease Prevention and Control (ECDC). 9 A single strain was derived from the first sample collected in the case of the first episode of infection; during recurrent infection, a further strain was qualified for the study, provided that 14 days had passed since the first episode of infection, in the absence of clinical symptoms between the episodes. To confirm a diagnosis of BSI, at least 2 samples were taken. In the cases when a blood sample was taken to confirm a diagnosis of pneumonia, the bacterial isolate was treated as the cause of pneumonia (if lacking an isolate from bronchoalveolar lavage fluid).
Relevant information about the patients, such as age, sex, type of infection, and place of hospitalization was also collected. According to information gathered by the collaborating laboratories, patients were classified as one of the following: hospital patients; patients from ICUs (n = 146; 57.7%), the Department of Internal Medicine (n = 63; 24.9%) or the pulmonary medicine ward (n = 29; 11.5%); or outpatients, including residents of long-term care facilities (LTCFs), people with infections diagnosed by a physician, and those staying in nursing homes or receiving home care (n = 15; 5.9%). The tested strains came from pneumonia (n = 197; 77.9%), BSIs (n = 52; 20.5%) and meningoencephalitis (n = 4; 1.6%).
Bacterial isolates
In 2013, 2,763 samples were examined in the collaborating laboratories. Microbiological examinations were performed on blood (1,721 samples), pleural puncture fluid (124 samples), and tracheobronchial aspirates and bronchoalveolar lavage fluid, when available (918 samples).
Microorganisms were identified using a semi-automatic system (Phoenix; Becton-Dickinson, Warszawa, Poland), according to standard methods. Among the samples tested, 253 were positive for pathogens belonging to NFBs. The studied strains belonged to the following groups: 1) ACI (Acinetobacter baumannii, n = 125; Acinetobacter junii, n = 1; Acinetobacter radioresistens, n = 1; Acinetobacter lwoffii, n = 1; and Acinetobacter ursingii, n = 1);
2) PAR (Pseudomonas aeruginosa, n = 86; and Pseudomonas putida, n = 4); or 3) Others (Stenotrophomonas maltophilia, n = 26; Achromobacter denitrificans, n = 5; Comamonas testosteroni, n = 1; Ochrobactrum anthropi, n = 1; and Alcaligenes faecalis, n = 1).
Drug resistance
Susceptibility testing was performed using a semi-automatic system (Phoenix NMIC/ID-204; Becton-Dickinson, Warszawa, Poland). Antimicrobial susceptibility was assessed according to the current European Committee on Antimicrobial Susceptibility Testing guidelines (EU-CAST; clinical breakpoint tables v. 5.0), 10 . For all strains, antimicrobial susceptibility testing for colistin was performed using the E-test strips (bioMérieux, Warszawa, Poland). Twenty antibiotics from 11 antimicrobial categories were tested: aminoglycosides, carbapenems, cephalosporins, cephalosporins and inhibitors, fluoroquinolones, folate pathway inhibitors, monobactams, penicillins, penicillins and β-lactamase inhibitors, polymyxins, and tetracyclines. For S. maltophilia (STM), only trimethoprim-sulfamethoxazole was tested, according to the EUCAST guidelines. Resistance for an antimicrobial category meant resistance to all antimicrobial agents in the category (according to the above description).
Different patterns of resistance were defined according to Magiorakos et al. with the following modifications: 1) bacteria not susceptible to at least 1 agent in 3 or more antimicrobial categories were considered to be MDR strains; 2) bacteria not susceptible to at least 1 agent in more than 1 or 2 antimicrobial categories were considered to be XDR strains; and 3) bacteria not susceptible to any agents in any antimicrobial categories were considered to be PDR strains.
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DiversiLab typing
Epidemiological typing of 101 A. baumannii strains from 2 ICUs (only) was performed by repetitive polymerase chain reaction (rep PCR) (DiversiLab System; bioMérieux, Warszawa, Poland) as previously described. 4 Isolates that clustered ≥91.3% were considered related.
Statistical methods
The differences between 2 groups of patients with an infection caused by Acinetobacter spp. vs Pseudomonas spp. isolates were evaluated with an unpaired t-test (Welsh's t-test). Analysis of variance was used to compare multiple parameters, and their frequency was compared with the χ 2 test or G-test (Table 1 ). The association between etiology and the type of infections, and the type of units, etc. was measured with an odds ratio (OR) and a 95% confidence interval (CI). Factorial ANO-VA model (logit link function and Poisson distribution of dependent variables) was used to check the influence of sex, age and type of ward on the number of antibiotic groups for which strains (ACI and PAR) were resistant ( Table 4 ). The computer software package Statistica PL v. 6.0 was applied, and p < 0.05 was regarded as significant. NFB -non-fermentative bacilli; ICU -intensive care unit; LTCF -long-term care facility; BSI -bloodstream infection; SD -standard deviation; * Others included: Stenotrophomonas maltophilia, n = 26; Achromobacter denitrificans, n = 5; Comamonas testosteroni, n = 1; Ochrobactrum anthropi, n = 1; and Alcaligenes faecalis, n = 1.
Ethics
The use of data collected for scientific purposes of this study was approved by the Bioethics Committee of Jagiellonian University Medical College (No. KBET/362/B/2012). All data entered into the electronic database and analyzed during this research were previously anonymized and de-identified.
Results
Study population
The average age of the study population was 60.8 years (SD: 16.3 years). There was a predominance of males (n = 174); however, there was no association between the occurrence of microbial species and the sex or age of patients ( Table 1 ). The age of outpatients differed from the age of inpatients and LTCF patients; significantly older patients received home care or stayed in LTCFs, and significantly younger patients were treated in hospital (Table 1) .
ACI strains came significantly more often from ICU wards, whereas PAR strains were from pulmonology wards, outpatients, and residents of LTCFs (g 2 = 52.762; p < 0.0001) ( Table 1 ). The tested NFB strains appeared with different frequencies in different types of infections. The highest prevalence of ACI and PAR was found in pneumonia, and STM in BSIs ( Table 2) . Regardless of the type of unit, PAR strains were significantly less frequent in pneumonia than ACI (OR: 0.21; 95% CI: 0.133-0.335), and in BSIs, strains from the Others group were significantly more frequently observed compared with other infections (OR: 4.74; 95% CI: 2.208-10.19) ( Table 2) . Differentiating between ICU and non-ICU units, ACI strains were significantly more frequent in pneumonia in ICUs than other species (OR: 5.8; 95% CI: 3.11-10.86) ( Table 2 ). In the case of BSI, there were considerably more isolated strains from the Others group in non-ICU units than other species (OR: 25.3; 95% CI: 4.75-134.89) ( Table 2 ).
Drug resistance
More than 75% of ACI strains were resistant to 14 of 16 antimicrobials. Among ACI strains, the proportion of XDR strains was the highest among all 3 studied groups of pathogens (n = 99; 76.1%), and most of these isolates were resistant to all studied antibiotics with the exception of colistin (n = 76; 58.9%) ( Table 3 ). The minimal inhibitory concentration (MIC 50 ) for colistin in the ACI group was 1 mg/L. Two PAR strains (2.2%) were resistant to all studied antibiotics with the exception of netilmicin and colistin. XDR PAR strains were less common than XDR ACI, 8.9% vs 76.1% (OR: 0.049; 95% CI: 0.022-0.109). MDR strains occurred with a frequency of 28.9% (n = 26) ( Table 3 ). The MIC 50 for colistin in the PAR group was 1 mg/L.
In strains from the Others group, 97% were susceptible to sulphametoxazole-trimetoprim (SXT), and only 1 -S. maltophilia -was resistant to SXT.
No PDR strains were identified in the studied group. Almost 60% of ACI strains were nearly PDR strains, and they were susceptible only to polymyxin antimicrobials.
Factorial ANOVA analysis
In the model of factorial analysis, the Poisson distribution of the dependent variable (effect) and the logit link function were assumed. The model showed a significant fit (χ 2 = 151.5078; df = 9; p < 0.0001). The analysis of parameters (Table 4) shows that the NFBs isolated from infections in ICUs were resistant to more antibiotic groups than isolates from other wards. In addition, ACI organisms were resistant to more antibiotic groups than the PAR organisms (STM were not considered in the model).
DiversiLab typing
DiversiLab demonstrated the presence of 2 dominant clones in the ACI group. Clone 1 included 24 isolates and clone 2 included 55 isolates. Both of these clones were classified as European Clone 2 (EUII). Other listed clones (3-6) consisted of 2 strains. Twelve strains were distinguished as unique. Two isolates were non-typable. Most isolates belonging to clone 1 (67.8%) and clone 2 (80%) were susceptible only to colistin. Among the unique isolates, 30% had a pattern of resistance to colistin alone.
Discussion
Non-fermentative Gram-negative bacilli have emerged as major agents of pneumonia (especially ventilator-associated), and their resistance to antibiotics, particularly to carbapenems, has become a therapeutic challenge.
Acinetobacter baumannii has become one of the most difficult nosocomial pathogens to control and treat, with a mortality rate of ~30%, 12 and P. aeruginosa is a highly virulent organism with a mortality rate of 40-60%. 5 Acinetobacter baumannii can also cause bloodstream, urinary tract, and wound infections. 13 In our study, the highest prevalence of ACI and PAR was found in pneumonia, and STM was significantly more frequently observed in BSIs.
The most serious issue in the treatment of A. baumannii infection are XDR strains, because the number of active agents is limited.
14 Our study also showed that the greatest problem was the extremely drug-resistant A. baumannii (76%), compared with MDR strains (14.6%).
The highest resistance among A. baumannii strains in our study was observed for aminoglycosides, cephalosporins, fluoroquinolones, carbapenems, and SXT. According to the European Antimicrobial Resistance Surveillance Network (EARS-Net), antibiotic resistance MDR -multidrug-resistant; XDR -extensively drug-resistant; PDR -pandrug-resistant; n/a -not applicable. In 2010, the European Centre for Disease Prevention and Control (ECDC) reported that ~15% of P. aeruginosa strains were MDR, in contrast to 1993, when the reported value was only 4%. 16 It is worrying to note that 1/3 of the isolates were MDR, and 8.9% were XDR. Taken together, this means that ~40% of the population are at risk of serious problems with the treatment of severe infections, such as BSI and pneumonia.
According to EARS-Net, ~32.3% of the PAR isolates from invasive infections in 2013 were carbapenem-resistant, which is comparable to our results (about 1/3 of the studied strains were resistant to imipenem). This is more than in previous reports from Poland, where only 10.5% of the isolates were carbapenem-resistant. 17 We also noted a high number of PAR strains resistant to aminoglycosides (~30%). Such a problem does not exist in countries such as Sweden (3%) or Norway (1.5%), but the situation is different in Greece (40%) or the Czech Republic (25%). 15 The percentage of strains resistant to fluoroquinolones is also worrying, as about half of the tested strains were resistant. This rate is also higher than in Scandinavian countries, where <10% of strains isolated from invasive infections are resistant to those antimicrobials. Furthermore, attention should be paid to the use of fluoroquinolones. Similar results were obtained in the case of urinary tract infections caused by PAR in Poland, which is understandable, as those antimicrobials are intended for use in urinary tract infections. 18 Carbapenem-resistant strains are mostly susceptible to polymyxins; however, these antimicrobials are known to be toxic and are used as drugs of last resort. In our study, the greatest therapeutic problem was represented by the strains that were nearly pandrug-resistant and susceptible only to colistin. No strains resistant to colistin were reported in Poland.
It is of particular interest that, in our study, BSIs were frequently caused by bacteria from the OTHERS group, mainly STM. The World Health Organization (WHO) classified this pathogen as one of the leading MDROs in hospital settings. 19 STM causes a wide range of infections, including respiratory tract infections and BSIs. Despite the large number of different global surveillance studies, there are still limited data on the prevalence and susceptibility patterns of STM. 20 The worldwide prevalence of STM in BSIs was ~0.8% in 2000-2004. 21 It is difficult to assess how large the problem with STM was in our study population, because there were no data from other multicenter studies. However, reports from the German KISS program show a growing involvement of STM in the etiology of hospital infections, and the proportion of STM increased from 1.646 to 2.102 between 2001 and 2004. 21 There are limited antimicrobial options for infections due to STM because of its extensive resistance to most antibiotics. One drug recommended as a drug of choice is SXT. 22 Resistance rates may vary between different regions but, in general, they are <10%. 23, 24 One study from Poland on a set of 80 STM clinical isolates showed that only 71.3% of the strains were susceptible to SXT. 25 Here, we detected only 1 resistant strain, which is not consistent with previous reports.
Conclusions
Our results indicate serious potential therapeutic problems related to the high antibiotic resistance of A. baumannii isolates. The stratification of drug resistance (MDR/XDR/PDR) may become an important tool for the assessment of public health epidemiology and microbiological hazards at the local, national, and international levels. It allows a clear presentation of the issues concerning the epidemiology of highly resistant bacilli, and the exchange of information between medical staff and local representatives of public health for the implementation of effective measures to reduce drug resistance. The growing prevalence of MDR and XDR is challenging for clinicians, because the treatment options are limited. New antimicrobial agents and treatment protocols are needed.
